NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Helix BioPharma's Interim Financial Statements Filing for Q1 2026
TL;DR
Helix BioPharma's financial filings show transparency, potentially boosting investor confidence and providing an edge in oncology innovation competition.
Helix BioPharma filed unaudited interim financial statements for Q3 2025, including MD&A and CEO/CFO certifications, available on SEDAR+ and their website.
Helix BioPharma's oncology pipeline aims to make hard-to-treat cancers vincible, potentially improving survival and quality of life for cancer patients worldwide.
Helix BioPharma's L-DOS47 targets CEACAM6-expressing tumors to enhance therapy sensitivity, while their oral drugs like LEUMUNA could revolutionize cancer treatment delivery.
Found this article helpful?
Share it with your network and spread the knowledge!
Helix BioPharma Corp. has filed its unaudited interim financial statements, management's discussion and analysis (MD&A), and CEO/CFO certifications for the three-month period ended October 31, 2025.
The company filed unaudited interim financial statements, management's discussion and analysis (MD&A), and CEO/CFO certifications. These documents are available on the Company's profile at www.sedarplus.ca and on its website at https://www.helixbiopharma.com/filings-and-financials/.
Helix BioPharma is a clinical-stage oncology company focused on developing near-term solutions for today's hardest-to-treat cancers through innovative treatments like antibody-enzyme conjugates and antibody-drug conjugates.
The pipeline includes Tumor Defense Breaker™ L-DOS47 (in clinical stage for NSCLC), next-generation bi-specific antibody-drug conjugates in discovery, LEUMUNA™ (oral immune checkpoint modulator for post-transplant leukemia relapse), and GEMCEDA™ (first-in-class oral gemcitabine prodrug for advanced cancers).
The company is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0).
Investors can contact Helix BioPharma Corp. at their Toronto office (40 Temperance Street, Suite 2700) by phone (+1 857 208 7687) or email Jacek Antas, Director, at corporate@helixbiopharma.com.
Forward-looking statements include financial projections, plans, goals, and expectations about the company's future business, operations, and research activities. They are included as required by Canadian securities laws but are not historical facts and involve risks and uncertainties.
The financial statements cover the three-month period ended October 31, 2025, which represents the company's first quarter of fiscal year 2026.
Curated from NewMediaWire
